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The Editorial on the Research Topic
Inhibiting PARP as a Strategic Target in Cancer
When Christina Annunziata and I embarked on guest editing an e-journal about poly(ADP-ribose) 
polymerase (PARP) inhibitors for cancer therapy, our goal was to capture how one of the most 
promising, rationally developed therapies had become increasingly complex in clinical use. We 
recruited an outstanding group of researchers to help in this effort. We organize their contributions 
into two broad categories, those with a more basic science approach and those with a more clinical 
approach, although these are not without overlap.
Beginning with the more mechanistic contributions, “The Elephant and the Blind Men: Making 
Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells” by De Lorenzo 
et al. provides an excellent review of the main models proposed to explain the synthetic lethality 
seen with PARP inhibition and deficiency in homologous recombination. Limitations of the models 
are highlighted, along with the potential impact that our knowledge gaps might have on clinical 
application of PARP inhibition. This article provides the groundwork for critical consideration of 
the other papers in this compilation.
In “Strategic Combination of DNA Damaging Agent and PARP Inhibitor Results in Enhanced 
Cytotoxicity,” Horton and Wilson describe using a mouse embryonic fibroblast cell culture model to 
better understand how PARP-1 inhibition impacts cell killing in combination with various chemo-
therapeutic agents. They report that the chemistry of the DNA repair intermediate that is formed is 
critical to PARP inhibitor-induced sensitization. This level of detail complements that presented by 
Steffen et al. who contributed “Structural Implications for Selective Targeting of PARPs.” The authors 
delve into the question of whether PARP inhibition should be targeted to all PARPs through binding 
to conserved regions or more selective in targeting specific PARPs. The answer has the potential to 
impact both PARP inhibitor effectiveness and toxicity.
Poly(ADP-ribose) polymerase enzymes are most widely recognized for their roles in single-strand 
DNA repair, especially when complementing the double-strand repair that is dependent on BRCA 
proteins. It is important to realize, however, that the PARP enzymes have other functions in the cell. 
In “Beyond DNA Repair: Additional Functions of PARP-1 in Cancer,” Weaver and Yang broaden our 
focus on PARP inhibition from the typically discussed DNA damage response to other processes, 
such as inflammation, angiogenesis, cellular metabolism, and cell death, that are critical to cancer 
biology. This information helps interpret some side effects of the PARP inhibitors in the clinic and 
hints at pathways to co-target in the future. In the group of more clinical contributions, Shah et al. 
build on this theme by discussing the clinical impact of our lack of complete understanding of the 
mechanism of action of PARP inhibitors in their contribution, “PARP Inhibitors in Cancer Therapy: 
Magic Bullets but Moving Targets.”
2Zorn and Annunziata Editorial: Inhibiting PARP in Cancer
Frontiers in Oncology | www.frontiersin.org April 2016 | Volume 6 | Article 91
Key perspectives on the clinical development process of PARP 
inhibitor development unfold in additional articles included in 
the compilation. Ricks et  al. discuss the development of PARP 
inhibitors from the perspective of the US Food and Drug 
Administration. In “Successes and Challenges of PARP Inhibitors 
in Cancer Therapy,” they provide insight into the regulatory 
aspects of the development process from the phase 0 veliparib 
trial to the current approval of olaparib for limited clinical use. 
Adding to this series, Burgess and Puhalla discuss clinical tri-
als from their perspective as academic physicians. They have 
contributed an in-depth review of the use of PARP inhibitors in 
clinical trials to date in breast and ovarian cancer. Their review in 
“BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian 
Cancers: More Alike than Different” provides a window into the 
biologic factors that might influence response to PARP inhibi-
tion. Additional detail is teased out, with relevance to women’s 
malignancies, in “The Role of PARP Inhibitors in the Treatment 
of Gynecologic Malignancies.” Here, Reinbolt and Hays review 
the data on the use of PARP inhibitors in ovarian, endometrial, 
and cervical cancer, and discuss their vision regarding future 
directions for their development. O’Sullivan et al. provide a com-
plementary direction in “Beyond Breast and Ovarian Cancers: 
PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like 
Solid Tumors.” Importantly, they broaden potential application 
with respect to tumor type, but focus on the molecular aspects 
that may help optimize PARP inhibitor use in a defined patient 
population. Specifically, these authors review the data for PARP 
inhibitor use in solid tumors other than breast and ovarian can-
cer, helping to frame the potential for expanded use in the future.
This collection of articles addresses the role of PARP inhibition 
in cancer therapy, from both basic science and clinical research 
perspectives. The integration of bench and bedside aspects is vital 
for moving the field forward to the most efficacious use of these 
agents. While our knowledge of PARP inhibitors has grown sub-
stantially in a relatively short amount of time, critical issues, such 
as mechanisms of action, appropriate therapeutic combinations, 
limiting short- and long-term toxicity, and defining the ideal 
patient population, remain to be resolved. We have compiled 
these articles to stimulate thoughts and discussion regarding this 
promising line of therapy, and expedite the successful application 
to patients.
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